How can the Quality of Medical Data in Pharmacovigilance, Pharmacoepidemiology and Clinical Studies be Guaranteed? - 08/07/16
participants of round table N° 2 of Giens Workshops XXVIII:
Philippe Barthélémy 4, Sophie Brisset 5, Dominic Cellier 6, Olivier Chassany 7, Jean-Paul Demarez 8, Vincent Diebolt 9, Alain Francillon 10, Laetitia Gambotti 11, Hakima Hannachi 12, Philippe Lechat 13, François Lemaire 14, Michel Lièvre 15, Christophe Misse 16, Marina Nguon 17, Antoine Pariente 18, Michel Rosenheim 19, Nadine Weisslinger-Darmon 20, †pages | 7 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Abstract |
The development of medicinal products is subject to quality standards aimed at guaranteeing that database contents accurately reflect the source documents. Paradoxically, these standards hardly address the quality of the source data itself. The objective of this work was to propose recommendations to improve data quality in three fields (pharmacovigilance, pharmacoepidemiology and clinical studies). The analysis was focused on the data and on the critical stages presenting critical quality problems, for which the current guidelines are insufficiently detailed, unsuitable and/or poorly applied. Finally, recommendations have been proposed, mainly focused on the origin of the data and its transcription.
Le texte complet de cet article est disponible en PDF.Keywords : quality, data, guidelines, clinical trials, pharmacoepidemiology, pharmacovigilance
Abbreviations : CONSORT, CRA, CRF, EMA, GRACE, ICH, ISPE, MA, MEDRA (dictionnary), PMSI, RMI, SNIIRAM, STROBE, SUSAR
Plan
Vol 68 - N° 4
P. 217-223 - juillet 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?